2021
DOI: 10.1002/lt.25957
|View full text |Cite
|
Sign up to set email alerts
|

A Multicentric Experience on Living Donor Liver Transplantation in Coronavirus Disease 2019 Hotspots in India

Abstract: As of August 2020, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has affected more than 213 countries, leading to more than 18 million cases and 690,000 deaths. India is the second most affected country, with the majority of cases in metropolitan cities, such as Mumbai, New Delhi, Chennai, and Bengaluru. There is limited literature on the outcomes and safety of performing living donor liver transplantation (LDLT) in coronavirus disease 2019 (COVID‐19) epicenters. Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 4 publications
0
10
0
Order By: Relevance
“…‐A multicentre study from India (LDLT = 31) reported on the perioperative safety and good outcomes in carefully timed LDLT (1 COVID‐19 infected), even in COVID‐19 hotspots 132 …”
Section: Liver Manifestations and Disease‐specific Management For Pat...mentioning
confidence: 99%
“…‐A multicentre study from India (LDLT = 31) reported on the perioperative safety and good outcomes in carefully timed LDLT (1 COVID‐19 infected), even in COVID‐19 hotspots 132 …”
Section: Liver Manifestations and Disease‐specific Management For Pat...mentioning
confidence: 99%
“…After excluding age, diabetes and chronic kidney disease significantly associated with mortality Polak 4 244 36 (14.7%) died, internet based survey Webb 34 39 Data from registry, 9 (23%) died, 4 of death happened in patients transplanted < 2 years back, 4 of died had diabetes and hypertension, 3 were obese Rabiee 35 112 25 (22.3%) died, LT recipients had lower acute liver injury when compared to age and sex matched CLD, reduction of immunosuppression was not associated with liver injury/mortality. ALI significantly associated with mortality Lee 36 38 7 died (18% overall, 29% of hospitalized) Dumortier 37 104 20 died, age independently associated with mortality Becchetti 38 57 7 died (12%), 5 of 7 mortalities happened in cases with history of cancers Colmenero 39 111 31.5% had severe disease, 20 (18%) mortality Webb 40 151 28 (19%) died, when compared to matched non-transplant population, mortality was not high in transplant recipients Dhampalwar 41 12 1 died Case reports or small series 32 , 42 , 43 , 44 , 45 , 46 27 9 died Total 1138 211 died (18.5%) …”
Section: Introductionmentioning
confidence: 99%
“…In a multicenter Indian study involving 31 living donor LT patients (21 adults and 10 pediatric patients) from April to July 2020, one patient developed SARS-CoV-2 infection 46 days after surgery and was recovering at the time of publication [45]. In this patient, mycophenolate mofetil was stopped, and the doses of tacrolimus and steroids were modified.…”
Section: Solid-organ Transplantation (Sot)mentioning
confidence: 99%
“…None of the donors or transplant team members developed SARS-CoV-2 infection during the study period. The authors emphasized the importance of maintaining strict protocol in preventing the development of COVID-19 in the recipients, donors, or transplant team members [45].…”
Section: Solid-organ Transplantation (Sot)mentioning
confidence: 99%